We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen to Buy Potential Alzheimer’s, Parkinson’s Drug From Pfizer
Biogen to Buy Potential Alzheimer’s, Parkinson’s Drug From Pfizer
Biogen has agreed to purchase Pfizer’s early-stage neurological disease drug for $75 million plus royalties and up to $635 million in future payments. The acquisition of PF-05251749 marks the latest move by Biogen into potential treatments for neurological diseases.